Product Name

Brilanestrant

General description

Brilanestrant is a potent ER-α binder (ER-α, IC50 = 6.1 nM ER-β, IC50 = 8.8 nM), a full transcriptional antagonist with no agonism and displays good potency and efficacy in ER-α degradation (EC50 = 0.7 nM) and MCF-7 breast cancer cell viability (IC50 = 2.5 nM) assays with good selectivity over other nuclear hormone receptors.

Synonym

GDC-0810, ARN-810

Purity

≥98.5%(HPLC)

CAS Number

1365888-06-7

Formula

C²⁶H²⁰ClFN²O²

Molecular Weight

446.9

Suitability

BioReagent, suitable for cell culture, etc.

l  Physical and Chemical Information

Appearance

Solid

Solubility(25°C)

DMSO

≥50mg/ml

Ethanol

≥50mg/ml

Water

Very slightly soluble

l  Biological Information

Biochem/Physiol  Actions

Brilanestrant is an orally available, nonsteroidal selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, brilanestrant binds to the estrogen receptor and induces a conformational change that results in the degradation of the receptor. This may inhibit the growth and survival of ER-expressing cancer cells.

l  Storage

Storage temp.

-20°C

l  Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses.

l  References

1.    http://www.drugbank.ca

2.    https://ncit.nci.nih.gov

3.    https://www.ncbi.nlm.nih.gov